Proteomics could also be vital to the future of the pharmaceutical industry, says Jessica Chutter, managing director and co-director of biotechnology for Morgan Stanley.
Morgan Stanley, a big investment bank, has bought stakes in three groups, Avenue Capital, FrontPoint Partners and Lansdowne, at a total cost believed to be more than $1 billion.